title: Long-term management of gemcitabine in a patient with advanced pancreatic cancer undergoing haemodialysis.
abstract: Gemcitabine application for patients with impaired renal function or undergoing haemodialysis will increase if the efficacy and safety are proved as the treatment for pancreatic cancer of these patients. However, there is no guideline about the usage of gemcitabine in patients with impaired renal function or haemodialysis. We report the case of a 70-year-old man with advanced pancreatic cancer undergoing haemodialysis. After discontinuation of 100% or 80% dosage, 60% dose of gemcitabine was administered biweekly. Serum carbohydrate antigen 19-9 and carcinoembryonic antigen levels were marked by slight variations and abdominal computed tomography (CT) showed the tumour size hardly changed. We administered gemcitabine for the patient 14 times in total, and he survived over 8 months from the definitive diagnosis. These findings confirm the efficacy and safety of treatment with a biweekly 60% dose of gemcitabine for patients with advanced pancreatic cancer undergoing haemodialysis in the face of dose modification.
authors.forename: Kazuki
authors.initials: K
authors.lastname: Takakura
authors.forename: Shigeo
authors.initials: S
authors.lastname: Koido
authors.forename: Akitaka
authors.initials: A
authors.lastname: Takahara
authors.forename: Shunichi
authors.initials: S
authors.lastname: Odahara
authors.forename: Jimi
authors.initials: J
authors.lastname: Mitobe
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsudaira
authors.forename: Shintaro
authors.initials: S
authors.lastname: Tsukinaga
authors.forename: Toyokazu
authors.initials: T
authors.lastname: Yukawa
authors.forename: Kei
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Keisuke
authors.initials: K
authors.lastname: Nagatsuma
authors.forename: Kan
authors.initials: K
authors.lastname: Uchiyama
authors.forename: Mikio
authors.initials: M
authors.lastname: Kajihara
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Ohkusa
authors.forename: Hisao
authors.initials: H
authors.lastname: Tajiri
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D006435:Renal Dialysis; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine
keywords: Dose modification; Gemcitabine,; Haemodialysis,; Pancreatic cancer,